PMID- 24289602
OWN - NLM
STAT- MEDLINE
DCOM- 20140812
LR  - 20211203
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 14
IP  - 10
DP  - 2013
TI  - Roles of mTOR and p-mTOR in gastrointestinal stromal tumors.
PG  - 5925-8
AB  - OBJECTIVE: This study aimed to examine the relationship between expression of 
      mammal target of rapamycin (mTOR) and phosphorylation of mTOR (p-mTOR) protein in 
      the PI3K/Akt/mTOR signaling pathways in gastrointestinal stromal tumors and 
      relatiuonships with clinical factors. METHODS: Immunohistochemistry was used to 
      detect the expression of the associated proteins mTOR, p-mTOR, and 
      phosphorylation of the tumor suppressor genes PTEN, P27, VEGF, and EGFR in 40 
      cases of gastrointestinal stromal tumors, with division into a very low and low 
      risk group as well as a moderate and high risk group. RESULTS: The positive rate 
      of mTOR and p-mTOR was significantly increased in the moderate and high risk 
      group compared with the very low and low risk group. The difference was 
      statistically significant (P<0.05). When grouped according to size, the positive 
      mTOR expression rate exhibited a statistical difference (P<0.05), which was 
      significantly increased in the group of tumors larger than 5 cm. The difference 
      in the positive mTOR and p-mTOR expression rate exhibit no statistical 
      significance among the PTEN, P27, VEGF, and EGFR expression subgroups (P>0.05). 
      CONCLUSION: The different expressions of mTOR and p-mTOR in the signal 
      transduction pathway of gastrointestinal stromal tumor in the different 
      degree-of-risk groups suggested that the mTOR and p-mTOR of the signal 
      transduction pathway serve an important function in the occurrence and 
      development of gastrointestinal stromal tumors.
FAU - Li, Jun-Chuan
AU  - Li JC
AD  - Department of Pathology, The First Affiliated Hospital of Yangtze University, 
      Jingzhou, China E-mail : hongyuzhucn@163.com.
FAU - Zhu, Hong-Yu
AU  - Zhu HY
FAU - Chen, Ting-Xuan
AU  - Chen TX
FAU - Zou, Lan-Ying
AU  - Zou LY
FAU - Wang, Xiao-Yan
AU  - Wang XY
FAU - Zhao, Hui-Chuan
AU  - Zhao HC
FAU - Xu, Jun
AU  - Xu J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CDKN1B protein, human)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*metabolism
MH  - Cyclin-Dependent Kinase Inhibitor p27/metabolism
MH  - ErbB Receptors/metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Stromal Tumors/*metabolism/pathology
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - PTEN Phosphohydrolase/metabolism
MH  - Phosphorylation
MH  - Prognosis
MH  - TOR Serine-Threonine Kinases/*metabolism
MH  - Vascular Endothelial Growth Factor A/metabolism
MH  - Young Adult
EDAT- 2013/12/03 06:00
MHDA- 2014/08/13 06:00
CRDT- 2013/12/03 06:00
PHST- 2013/12/03 06:00 [entrez]
PHST- 2013/12/03 06:00 [pubmed]
PHST- 2014/08/13 06:00 [medline]
AID - 10.7314/apjcp.2013.14.10.5925 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2013;14(10):5925-8. doi: 10.7314/apjcp.2013.14.10.5925.